Vol. 34 No. 1 (2019): Revista Uruguaya de Cardiología
Artículos de revisión

The best of the 2018 American Heart Association Meeting

Agustina Bonino
Ex-editora asociada de la Revista Uruguaya de Cardiología
Florencia Cristar
Editora asociada de la Revista Uruguaya de Cardiología
Published 19-11-2019

Keywords:

CONGRESSES, CARDIOLOGY, REDUCE-IT, VITAL, PIONEER-HF, PRINCESS TRIAL, HYPERTRIGLICERIDEMIA, VITAMIN D, SACUBITRIL-VALSARTÁN., HYPOTHERMIA

Abstract

The American Heart Association 2018 Congress was held in the city of Chicago, Illinois, from November 10 to 12. There were many news, three new recommendations guidelines were presented (approach to bradycardia and driving disorders, physical activity, and perhaps the most anticipated, the new treatment guide for dyslipidemia). In reviewing the 2013 recommendations, USexperts introduced several changes, the most important of which may be to reduce the significance of the 10-year risk calculation to refocus on the LDL goal, under the premise of that the lower, the better.
We will make a brief summary of some of the main scientific papers presented during this event that will undoubtedly have an important influence in the near future of global cardiology.

  • Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial-REDUCE-IT.
  • Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease- VITAL.
  • Angiotensin Receptor-Neprilysin Inhibition in Patients Hospitalized With Acute Decompensated Heart Failure: Primary Results of the PIONEER-HF Randomized Controlled Trial.
  • Pre-hospital Resuscitation Intra-arrest Cooling Effectiveness Survival Study-the PRINCESS Trial.